Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 43,334 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $19.00, for a total value of $823,346.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
NASDAQ:MNTA traded up $0.20 on Thursday, reaching $19.70. The company’s stock had a trading volume of 934,798 shares, compared to its average volume of 901,872. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $20.25. The company has a market capitalization of $1,448.78, a P/E ratio of -16.42 and a beta of 1.64.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The company had revenue of $64.60 million for the quarter, compared to the consensus estimate of $66.59 million. During the same quarter in the previous year, the business earned $0.60 earnings per share. The company’s revenue for the quarter was up 88.9% on a year-over-year basis. equities analysts expect that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current year.
A number of equities research analysts have commented on the company. Stifel Nicolaus upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the company from $18.00 to $21.00 in a research report on Thursday, February 22nd. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, April 4th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $15.33.
WARNING: This piece was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/12/momenta-pharmaceuticals-inc-mnta-ceo-sells-823346-00-in-stock.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.